Match!
Biology of Blood and Marrow Transplantation
IF
3.60
Papers
13540
Papers 10000
1 page of 1,000 pages (10k results)
Newest
#1Sylvia Dulan (City of Hope National Medical Center)
#2Kathie Viers (City of Hope National Medical Center)
Last. D.S. Synder (City of Hope National Medical Center)H-Index: 46
view all 13 authors...
Abstract As the world of cellular therapy expands to include immune effector cell (IEC) products such as commercial chimeric antigen receptor (CAR) T cells, quality management (QM) professionals are faced with creating either new IEC stand-alone programs or expand existing hematopoietic cell transplantation (HCT) programs to promote patient safety and be aligned with quality, regulatory, and accreditation requirements. The team professionals at City of Hope (COH) recently expanded the quality HC...
Source
#1Sue Shin (SNU: Seoul National University)H-Index: 13
#2Eun Young Song (SNU: Seoul National University)H-Index: 17
Last. Eun Youn Roh (SNU: Seoul National University)H-Index: 12
view all 7 authors...
Abstract Background : Induced pluripotent stem cells (iPSCs) have opened up unprecedented opportunities for novel therapeutic options for precision medicine. Hematopoietic stem cell (HSC) donor pools with previously determined human leukocyte antigen (HLA) types may be ideal sources for iPSC production. Based on the HLA distribution of cryopreserved cord blood units (CBUs) and registered bone marrow (BM) donors, we estimated how much of the Korean population could be covered by HLA-homozygous iP...
Source
Abstract The major hindrances to the success of a haploidentical HCT for hemoglobinopathies are graft failure, early post-transplant hemophagocytic syndrome (PTHPS) and graft-versus-host disease (GVHD). Following the successful incorporation of CTLA4Ig (Abatacept) in post-transplantation cyclophosphamide (PTCy) based haploidentical transplantation, we piloted this approach in 10 patients (age 3-19 years), with thalassemia major (TM, n=5) and sickle cell disease (SCD, n=5). Pretransplant immunosu...
Source
#1Yibo Wu (ZJU: Zhejiang University)
#2Jimin Shi (ZJU: Zhejiang University)H-Index: 27
Last. Yi Luo (ZJU: Zhejiang University)H-Index: 14
view all 9 authors...
Abstract Background Hematopoietic stem cell transplantation (HSCT) is increasingly being applied globally. Cases in which healthy HSCT donors are chronically infected with HBV are relatively common in areas where HBV is endemic. Recipients of stem cells from such HBsAg-positive donors are at risk of viral infection, and hence may develop HBV-related hepatitis. Given the lack of standardized approach to minimize such infections from HBsAg-positive donors during HSCT, we conducted this study with ...
Source
#2Shiyi Chenc Wilson Lam (U of T: University of Toronto)
Last. Rajat Kumar (U of T: University of Toronto)H-Index: 2
view all 12 authors...
Abstract We compared the outcomes of AML patients in complete remission treated with myeloablative conditioning (MAC) and reduced intensity conditioning (RIC). Additionally, we explored the efficacy of dual T-cell depletion using anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) for the prevention of graft-versus-host disease (GVHD) in RIC alloHCT. Between 2013 and 2018, 356 adults with AML in complete remission underwent allogeneic peripheral blood stem cell transplantat...
Source
#1Anne Conrad (UCBL: Claude Bernard University Lyon 1)H-Index: 4
Last. Christian Chidiac (UCBL: Claude Bernard University Lyon 1)H-Index: 26
view all 15 authors...
Abstract Background Data on immunogenicity and safety of the recommended revaccination schedule against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b (Hib) and hepatitis B in adult allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients is limited. Methods Prospective single-center cohort study (April 2014-March 2018) of adult allo-HSCT recipients referred to a dedicated vaccinology consultation and vaccinated with the pediatric combined DTaP(±HB)...
Source
Source
Abstract Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with two different methods of MESNA administration. Cumulative incidence of HC was lower in patients th...
Source
#1Maria-Luisa Schuber (Heidelberg University)
#2Sascha Dietrich (Heidelberg University)H-Index: 23
Last. Susanne Jung (Heidelberg University)
view all 14 authors...
Abstract Although CD19-directed chimeric antigen receptor (CAR) T cells have been successfully used after a preceding allogeneic stem cell transplantation (alloHCT) in patients with acute lymphoblastic leukemia, little is known about feasibility and outcome of CAR T cell treatment in patients who have been previously allotransplanted for lymphoma. In a single centre retrospective analysis, course and outcome of all allografted patients who have been treated with CD19 CAR constructs for B-cell ly...
Source
#1Laurent Garderet (University of Paris)H-Index: 44
#2Curly Morris ('QUB': Queen's University Belfast)H-Index: 15
Last. Patrick Hayden (Trinity College, Dublin)H-Index: 15
view all 7 authors...
Abstract Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard-of-care for transplant-eligible myeloma patients. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor (CAR) T-cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel age...
Source
12345678910
Top fields of study
Immunology
Hematopoietic stem cell transplantation
Transplantation
Diabetes mellitus
Medicine